文献速递艾滋病与性传播感染

非洲人群中多替拉韦神经精神不良事件与药代动力学及药物遗传学的关联

Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

在ADVANCE研究纳入的未接受过抗逆转录病毒治疗的非洲参与者中,评估多替拉韦暴露与治疗期间出现的神经精神不良事件之间的浓度-反应关系,并分析UGT1A1 rs887829和SLC22A2 rs316019多态性与不良事件的关联。药代动力学分析纳入464例,遗传学分析纳入301例。仅在第12周发现较高的多替拉韦暴露与睡眠质量恶化相关,但较高的多替拉韦暴露与MMS评分改善相关,提示可能有益处。

要点

  • 仅在第12周发现多替拉韦暴露与睡眠质量恶化相关。
  • 第12周和第24周较高的多替拉韦暴露与MMS评分改善相关。
  • UGT1A1和SLC22A2多态性与MMS评分或睡眠质量变化无关。

核心结论

  • 仅在第12周发现多替拉韦暴露与睡眠质量恶化之间存在关联证据,但较高的多替拉韦暴露与MMS评分改善相关,提示可能存在有益效应。

研究设计与样本

  • 在ADVANCE研究中随机分配至以多替拉韦为基础治疗的未接受过抗逆转录病毒治疗的参与者被纳入药代动力学子研究,药代动力学分析可用数据来自464例参与者,遗传学分析可用数据来自301例参与者。

主要发现

  • 通过多变量线性回归,较高的多替拉韦暴露仅在第12周与睡眠质量恶化相关(系数=-0.854,95%CI -1.703至-0.005,P=0.049)。
  • 较高的多替拉韦暴露在第12周与MMS评分改善相关(系数=-1.255,95%CI -2.250至-0.261,P=0.013),第24周亦与MMS评分改善相关(系数=-1.199,95%CI -2.030至-0.368,P=0.005)。
  • UGT1A1和SLC22A2多态性与MMS评分变化或睡眠质量变化无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dolutegravir has been associated with neuropsychiatric adverse events (NPAEs), but relationships between dolutegravir concentrations and NPAEs are unclear. OBJECTIVES: To determine in an African population whether a concentration-response relationship exists between dolutegravir and treatment-emergent NPAEs, and whether selected loss-of-function polymorphisms in genes encoding UDP-glucuronosyltransferase-1A1 (the major metabolizing enzyme for dolutegravir) and organic cation transporter-2 (involved in neurotransmitter transport and inhibited by dolutegravir) are associated with NPAEs. METHODS: Antiretroviral therapy-naive participants randomized to dolutegravir-based therapy in the ADVANCE study were enrolled into a pharmacokinetic sub-study. Primary outcome was change in mental health screening [modified mini screen (MMS)] and sleep quality from baseline to weeks 4, 12 and 24. Dolutegravir exposure was estimated using a population pharmacokinetic model. Polymorphisms analysed were UGT1A1 rs887829 and SLC22A2 rs316019. RESULTS: Data from 464 participants were available for pharmacokinetic analyses and 301 for genetic analyses. By multivariable linear regression, higher dolutegravir exposure was associated with worsening sleep quality only at week 12 [coefficient = -0.854 (95% CI -1.703 to -0.005), P = 0.049], but with improved MMS score at weeks 12 and 24 [coefficient = -1.255 (95% CI -2.250 to -0.261), P = 0.013 and coefficient = -1.199 (95% CI -2.030 to -0.368), P = 0.005, respectively]. The UGT1A1 and SLC22A2 polymorphisms were not associated with change in MMS score or sleep quality. CONCLUSIONS: Only at week 12 did we find evidence of a relationship between dolutegravir exposure and worsening sleep quality. However, higher dolutegravir exposure was associated with improved MMS scores, suggesting a possible beneficial effect.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Griesel R, Sinxadi P, Kawuma A, et al. Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population. J Antimicrob Chemother. 2022. PMID: 36031789. doi:10.1093/jac/dkac290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。